Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLS 004

Next Previous
Search
Drug Profile

SLS 004

Alternative Names: Gene therapy programme - Duke University/Seelos Therapeutics; LV-dCas9-DNMT3A; SLS-004

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University
  • Developer Duke University; Seelos Therapeutics
  • Class Antidementias; Antiparkinsonians; Gene therapies
  • Mechanism of Action Alpha-synuclein expression inhibitors; Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lewy body disease
  • No development reported Parkinson's disease

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
  • 31 Dec 2022 Preclinical trials in Parkinson's disease still ongoing in USA (Parenteral)
  • 15 Dec 2022 Preliminary pharmacodynamics data from preclinical studies in Parkinson's disease released by Seelos Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top